SzeleSTIM is a pioneering startup focused on providing innovative, non-invasive, and drug-free therapies to manage chronic pain and improve patient health. The company operates in the biomedical technology sector, specifically targeting the healthcare market. SzeleSTIM's primary clients are individuals suffering from chronic pain, a condition that significantly impacts quality of life and imposes a heavy burden on healthcare systems globally.

The core of SzeleSTIM's business model revolves around personalized auricular vagus nerve stimulation (VNS). This technique involves stimulating the vagus nerve through the ear to alleviate pain and promote healing. Unlike traditional pain management methods that often rely on medications, SzeleSTIM's approach is non-pharmacological, meaning it doesn't use drugs, and minimally invasive, which means it requires little to no surgical intervention.

SzeleSTIM's therapies are tailored to the individual needs of each patient, ensuring a personalized treatment plan. The company also emphasizes sustainability by using reusable components in their VNS devices, aligning with green technology principles. Additionally, SzeleSTIM incorporates advanced online pain management tools, including remote monitoring and closed-loop feedback systems. These tools allow for real-time pain measurement and therapy adjustments, optimizing treatment outcomes.

The company generates revenue by selling its VNS devices and related services to healthcare providers and directly to patients. By offering a subscription-based model for remote monitoring and ongoing support, SzeleSTIM ensures a steady income stream while providing continuous care to its clients.

SzeleSTIM has received significant funding from the European Horizon 2020 research and innovation program, highlighting its potential and credibility in the biomedical field.

Keywords: Chronic Pain, Vagus Nerve Stimulation, Non-Pharmacological, Personalized Therapy, Biomedical Technology, Healthcare, Remote Monitoring, Green Technology, Pain Management, Horizon 2020.